Plasma p-Cresol Lowering Effect of Sevelamer in Peritoneal Dialysis Patients: Evidence from a Cross-Sectional Observational Study

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Guida, Bruna ^a   Cataldi, Mauro ^a   Riccio, Eleonora ^a   Grumetto, Lucia ^a   Pota, Andrea ^a   Borrelli, Silvio ^b   Memoli, Andrea ^a   Barbato, Francesco ^a   Argentino, Gennaro ^a   Salerno, Giuliana ^a   Memoli, Bruno ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LANTHANUM; PARA CRESOL; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER;

ADULT; ALBUMIN BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEGRADATION KINETICS; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PROTEIN DEGRADATION; URINE VOLUME;

ADULT; AGED; CHELATING AGENTS; CRESOLS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PHOSPHATES; POLYAMINES;

EID: 84883424346     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073558     Document Type: Article

References (52)

1. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, et al. (2003) Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 63: 1934-1943.
2. Vanholder R, Glorieux G, Lameire N, (2003) European Uremic Toxin Work Group (2003) Uraemic toxins and cardiovascular disease. Nephrol Dial Transplant 18: 463-466.
3. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, et al. (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17: 2034-2047.
4. Cummings JH, (1983) Fermentation in the human large intestine: evidence and implications for health. Lancet 1: 1206-1209.
5. Evenepoel P, Meijers BKI, Bammens BRM, Verbeke K, (2009) Uremic toxins originating from colonic microbial metabolism. Kidney Int 76(Suppl 114): S12-S19.
6. Vanholder R, Bammens B, de Loor H, Glorieux G, Meijers B, et al. (2011) Warning: The unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant 26: 1464-1467.
7. Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, et al. (2010) Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant 25: 3693-3700.
8. Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, et al. (2008) Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 73: 1174-1180.
9. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, et al. (2010) p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 5: 1182-1189.
10. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, et al. (2010) Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 25: 1183-1191.
11. Cerini C, Dou L, Anfosso F, Sabatier F, Moal V, et al. (2004) P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 92: 140-150.
12. Meijers BK, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, et al. (2009) The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 54: 891-901.
13. Ying Y, Yang K, Liu Y, Chen QJ, Shen WF, et al. (2011) A uremic solute, P-cresol, inhibits the proliferation of endothelial progenitor cells via the p38 pathway. Circ J 75: 2252-2259.
14. Leypoldt JK, Cheung AK, Carroll CE, Stannard DC, Pereira BJ, et al. (1999) Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 33: 349-355.
15. Davenport A, (2011) Role of dialysis technology in the removal of uremic toxins. Hemodialysis International 15: S49-S53.
16. Krieter DH, Hackl A, Rodriguez A, Chenine L, Moragues HL, et al. (2010) Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrol Dial Transplant 25: 212-218.
17. Goto S, Yoshiya K, Kita T, Fujii H, Fukagawa M, (2011) Uremic toxins and oral adsorbents. TherApher Dial 15: 132-134.
18. Goldsmith DR, Scott LJ, Cvetković RS, Plosker GL, (2008) Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs 68: 85-104.
19. Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, et al. (2009) Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant 24: 278-285.
20. De Smet R, Thermote F, Lameire N, Vanholder R, (2004) Sevelamer-hydrochloride (Renagel) adsorbs the uremic compound indoxyl sulfate, indole and p-cresol. J Am Soc Nephrol 15: 505A.
21. Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, et al. (2010) Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 25: 2672-2679.
22. De Smet R, David F, Sandra P, Van Kaer J, Lesaffer G, et al. (1998) A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clinica Chimica Acta 278: 1-21.
23. Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlebaum Associates, Incorporated.
24. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1): S62-S69.
25. American Diabetes Association (2009) Executive Summary: Standards of medical care in diabetes-2009. Diabetes Care 32: S13-S61.
26. Evenepoel P, Claus D, Geypens B, Hiele M, Geboes K, et al. (1999) Amount and fate of egg protein escaping assimilation in the small intestine of humans. Am J Physiol 277: G935-G943.
27. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y, (2003) Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 64: 2238-2243.
28. Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, et al. (2011) Serum Concentration of p-Cresol and Indoxyl Sulfate in Elderly Hemodialysis Patients. Int. J. Geront. 5: 80-83.
29. Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, et al. (2008) Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int. 73: 1174-1180.
30. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76(Suppl 113): S1-S130.
31. Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, et al. (2005) Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 52: 290-295.
32. Ohno I, Yamaguchi Y, Saikawa H, Uetake D, Hikita M, et al. (2009) Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Intern Med 48: 415-420.
33. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, et al. (2005) Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 112: 2875-2882.
34. Ritz E, (2011) Intestinal-renal syndrome: mirage or reality? Blood Purif 31: 70-76.
35. McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, et al. (2011) Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 6: 133-141.
36. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y, (2006) Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 69: 1081-1087.
37. Niwa T, Ise M, Miyazaki T, Meada K, (1993) Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 65: 82-87.
38. Goto S, Yoshiya K, Kita T, Fujii H, Fukagawa M, (2011) Uremic toxins and oral adsorbents. Ther Apher Dial 15: 132-134.
39. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, et al. (2005) Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 149: 820-825.
40. Yamada K, Fujimoto S, Tokura T, Fukudome K, Ochiai H, et al. (2005) Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 27: 361-365.
41. Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, et al. (2008) Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 3: 61-68.
42. Shantouf R, Budoff MJ, Ahmadi N, Tiano J, Flores F, et al. (2008) Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol 28: 275-279.
43. Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, et al. (2008) Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron ClinPract 108: c278-283.
44. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, et al. (2012) Effects of Sevelamer on HbA1c, Inflammation, and Advanced Glycation End Products in Diabetic Kidney Disease. Clin J Am Soc Nephrol 7: 934-942.
45. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, Donate-Correa J, Cazaña-Pérez V, et al. (2011) Effect of Phosphate Binders on Serum Inflammatory Profile, Soluble CD14, and Endotoxin Levels in Hemodialysis Patients. Clin J Am Soc Nephrol 6: 2272-2279.
46. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C, (1999) Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658.
47. Perianayagam MC, Jaber BL, (2008) Endotoxin binding affinity of sevelamer hydrochloride. Am J Nephrol 28: 802-807.
48. Sun PP, Perianayagam MC, Jaber BL, (2009) Sevelamer hydrochloride use and endotoxin in hemodialysis patients: a pilot cross-sectional study. J Ren Nutr 19: 432-438.
49. Stinghen AE, Gonçalves SM, Bucharles S, Branco FS, Gruber B, et al. (2010) Sevelamer Decreases Systemic Inflammation in Parallel to a Reduction in Endotoxemia. Blood Purif. 29: 352-356.
50. Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM, (2003) Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 10: 133-145.
51. Imori S, Mori Y, Akita W, Takada S, Kuyama T, et al. Effects of Sevelamer hydrochloride on mortality, lipid abnormalityand arterial stiffness in hemodialyzed patients: a propensity matched observational study. Clin Exp Nephrol in press DOI 10.1007/s10157-012-0640-4.
52. Imori S, Mori Y, Akita W, Takada S, Kuyama T, et al. Effects of Sevelamer hydrochloride on mortality, lipid abnormalityand arterial stiffness in hemodialyzed patients: a propensity matched observational study. Clin Exp Nephrol in press DOI 10.1007/s10157-012-0640-4.